Fulcrum Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
De omzet en winst van Fulcrum Therapeutics zullen naar verwachting dalen met respectievelijk 91.5% en 32.6% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 32% per jaar.
Belangrijke informatie
-32.6%
Groei van de winst
-32.0%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.8% |
Inkomstengroei | -91.5% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | N/A | -77 | -62 | -57 | 5 |
12/31/2025 | N/A | -69 | -58 | -50 | 6 |
12/31/2024 | 80 | -10 | -8 | 0 | 8 |
9/30/2024 | 81 | -18 | -9 | -9 | N/A |
6/30/2024 | 82 | -20 | -13 | -12 | N/A |
3/31/2024 | 3 | -99 | -92 | -92 | N/A |
12/31/2023 | 3 | -97 | -91 | -91 | N/A |
9/30/2023 | 3 | -99 | -88 | -88 | N/A |
6/30/2023 | 3 | -98 | -93 | -92 | N/A |
3/31/2023 | 4 | -109 | -101 | -99 | N/A |
12/31/2022 | 6 | -110 | -99 | -97 | N/A |
9/30/2022 | 11 | -107 | -102 | -99 | N/A |
6/30/2022 | 14 | -104 | -96 | -94 | N/A |
3/31/2022 | 17 | -90 | -86 | -84 | N/A |
12/31/2021 | 19 | -81 | -80 | -78 | N/A |
9/30/2021 | 18 | -75 | -78 | -76 | N/A |
6/30/2021 | 15 | -73 | -60 | -58 | N/A |
3/31/2021 | 13 | -69 | -56 | -55 | N/A |
12/31/2020 | 9 | -71 | -55 | -54 | N/A |
9/30/2020 | 5 | -69 | -39 | -38 | N/A |
6/30/2020 | 3 | -68 | -48 | -47 | N/A |
3/31/2020 | 1 | -68 | -46 | -45 | N/A |
12/31/2019 | N/A | -90 | -40 | -39 | N/A |
9/30/2019 | N/A | -85 | -46 | -41 | N/A |
6/30/2019 | N/A | -79 | -38 | -32 | N/A |
3/31/2019 | N/A | -71 | -34 | -26 | N/A |
12/31/2018 | N/A | -39 | -32 | -23 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van FULC zal naar verwachting de komende 3 jaar dalen ( -91.5% per jaar).
Hoge groei-inkomsten: De omzet van FULC zal naar verwachting de komende 3 jaar dalen ( -91.5% per jaar).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van FULC naar verwachting over 3 jaar hoog zal zijn